Cargando…
Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
BACKGROUND: Medication adherence is a crucial component in the management of patients with chronic diseases needing a long-term pharmacotherapy. Parkinson’s disease (PD) is a chronic, degenerative disease with complex drug treatment that poses challenging barriers to patient adherence. The adoption...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136049/ https://www.ncbi.nlm.nih.gov/pubmed/35645779 http://dx.doi.org/10.3389/fnagi.2022.900029 |
_version_ | 1784714090795499520 |
---|---|
author | Tosin, Michelle H. S. Goetz, Christopher G. Bispo, Dharah P. C. F. Ferraz, Henrique B. Leite, Marco Antonio A. Hall, Deborah A. Stebbins, Glenn T. Oliveira, Beatriz Guitton R. B. |
author_facet | Tosin, Michelle H. S. Goetz, Christopher G. Bispo, Dharah P. C. F. Ferraz, Henrique B. Leite, Marco Antonio A. Hall, Deborah A. Stebbins, Glenn T. Oliveira, Beatriz Guitton R. B. |
author_sort | Tosin, Michelle H. S. |
collection | PubMed |
description | BACKGROUND: Medication adherence is a crucial component in the management of patients with chronic diseases needing a long-term pharmacotherapy. Parkinson’s disease (PD) is a chronic, degenerative disease with complex drug treatment that poses challenging barriers to patient adherence. The adoption of best practices of scale development can contribute to generate solid concepts and, in the long run, a more stable knowledge base on the underlying constructs of medication adherence in PD measured by the items of the first scale to be created for this purpose. PURPOSE: To present the development process and clinimetric testing plan of the Parkinson’s Disease Medication Adherence Scale (PD-MAS). METHOD: We adopted a hybrid approach plan based on the United States Food and Drug Administration and Benson and Clark Guide that will create a patient-reported outcome instrument. We presented an overview of consecutive and interrelated steps, containing a concise description of each one. International research centers from Brazil and United States were initially involved in the planning and implementation of the methodological steps of this study. RESULTS: We developed a four-phase multimethod approach for the conceptualization and the clinimetric testing plan of the PD-MAS. First, we describe the development process of the conceptual framework of the PD-MAS underpinning the scale construct; second, we formalized the development process of the first version of the PD-MAS from the generation of item pools to the content validation and pre-testing; third, we established the steps for the first pilot testing and revision; fourth, we describe the steps plan for the first pilot testing and revision, to finally describe its clinimetric testing plan and validation. CONCLUSION: The overview presentation of the development phases and the clinimetric testing plan of the PD-MAS demonstrate the feasibility of creating an instrument to measure the multidimensional and multifactorial components of the medication adherence process in people with PD. |
format | Online Article Text |
id | pubmed-9136049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91360492022-05-28 Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan Tosin, Michelle H. S. Goetz, Christopher G. Bispo, Dharah P. C. F. Ferraz, Henrique B. Leite, Marco Antonio A. Hall, Deborah A. Stebbins, Glenn T. Oliveira, Beatriz Guitton R. B. Front Aging Neurosci Neuroscience BACKGROUND: Medication adherence is a crucial component in the management of patients with chronic diseases needing a long-term pharmacotherapy. Parkinson’s disease (PD) is a chronic, degenerative disease with complex drug treatment that poses challenging barriers to patient adherence. The adoption of best practices of scale development can contribute to generate solid concepts and, in the long run, a more stable knowledge base on the underlying constructs of medication adherence in PD measured by the items of the first scale to be created for this purpose. PURPOSE: To present the development process and clinimetric testing plan of the Parkinson’s Disease Medication Adherence Scale (PD-MAS). METHOD: We adopted a hybrid approach plan based on the United States Food and Drug Administration and Benson and Clark Guide that will create a patient-reported outcome instrument. We presented an overview of consecutive and interrelated steps, containing a concise description of each one. International research centers from Brazil and United States were initially involved in the planning and implementation of the methodological steps of this study. RESULTS: We developed a four-phase multimethod approach for the conceptualization and the clinimetric testing plan of the PD-MAS. First, we describe the development process of the conceptual framework of the PD-MAS underpinning the scale construct; second, we formalized the development process of the first version of the PD-MAS from the generation of item pools to the content validation and pre-testing; third, we established the steps for the first pilot testing and revision; fourth, we describe the steps plan for the first pilot testing and revision, to finally describe its clinimetric testing plan and validation. CONCLUSION: The overview presentation of the development phases and the clinimetric testing plan of the PD-MAS demonstrate the feasibility of creating an instrument to measure the multidimensional and multifactorial components of the medication adherence process in people with PD. Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9136049/ /pubmed/35645779 http://dx.doi.org/10.3389/fnagi.2022.900029 Text en Copyright © 2022 Tosin, Goetz, Bispo, Ferraz, Leite, Hall, Stebbins and Oliveira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Tosin, Michelle H. S. Goetz, Christopher G. Bispo, Dharah P. C. F. Ferraz, Henrique B. Leite, Marco Antonio A. Hall, Deborah A. Stebbins, Glenn T. Oliveira, Beatriz Guitton R. B. Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan |
title | Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan |
title_full | Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan |
title_fullStr | Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan |
title_full_unstemmed | Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan |
title_short | Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan |
title_sort | parkinson’s disease medication adherence scale: conceptualization, scale development, and clinimetric testing plan |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136049/ https://www.ncbi.nlm.nih.gov/pubmed/35645779 http://dx.doi.org/10.3389/fnagi.2022.900029 |
work_keys_str_mv | AT tosinmichellehs parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT goetzchristopherg parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT bispodharahpcf parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT ferrazhenriqueb parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT leitemarcoantonioa parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT halldeboraha parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT stebbinsglennt parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan AT oliveirabeatrizguittonrb parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan |